Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment
Authors:
Open Access
Abstract
Bone metastases represent a lethal condition that frequently occurs in solid tumors such as prostate, breast, lung, and renal cell carcinomas, and increase the risk of skeletal-related events (SREs) including pain, pathologic fractures, and spinal cord compression. This unique metastatic niche consists of a multicellular complex that cancer cells co-opt to engender bone remodeling, immune suppression, and stromal-mediated therapeutic resistance. This review comprehensively discusses clinical challenges of bone metastases, novel preclinical models of the bone and bone marrow microenviroment, and crucial signaling pathways active in bone homeostasis and metastatic niche. These studies establish the context to summarize the current state of investigational agents targeting BM, and approaches to improve BM-targeting therapies. Finally, we discuss opportunities to advance research in bone and bone marrow microenvironments by increasing complexity of humanized preclinical models and fostering interdisciplinary collaborations to translational research in this challenging metastatic niche.Keywords
Funding Information
- National Institutes of Health (UG3CA260692)
- National Institute of Health (P30CA014520, T32 HL07899)
- U.S. Department of War (W81XWH-18-1-0273, W81XWH-16-1-0514)
- U.S. Department of Veterans Affairs (Advanced Fellowship in Women’s Health)
This publication has 309 references indexed in Scilit:
- Microfluidic devices for cell cultivation and proliferationBiomicrofluidics, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METNature Medicine, 2012
- Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growthBone, 2012
- Bone marrow and the control of immunityCellular & Molecular Immunology, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone CellsCancer Cell, 2011
- The amazing osteocyteJournal of Bone and Mineral Research, 2010
- Dickkopf‐1 (DKK‐1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastasesThe Prostate, 2010
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival SignalsCancer Cell, 2009